Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingObservational

A Comprehensive Breast Cancer Survivorship Biorepository

NCT ID: NCT05786664Sponsor: University of Southern CaliforniaLast updated: 2026-05-28

Summary

This study collects blood samples as well as clinical and self-report data from stage I-III breast cancer survivors to create a biorepository for future use. The creation of this biorepository will allow for future research into links between individual, molecular, and genomic signatures and cancer outcomes.

Detailed description

PRIMARY OBJECTIVE: I. To create an annotated biorepository with prospectively collected blood samples from breast cancer survivors. SECONDARY OBJECTIVES: I. To collect comprehensive data on social determinants of health (e.g., race/ethnicity, acculturation, socioeconomic status, and access to care), environmental exposures (based on zip codes/geocoding), lifestyle (e.g., diet, tobacco use), clinicopathologic characteristics, treatment history, follow-up and current disease status, survivorship-related issues. II. To establish an efficient process for researchers to utilize the biorepository for breast cancer and survivorship-related studies. OUTLINE: Patients complete surveys, undergo collection of blood samples, and review of medical records on study.

Arms & interventions

  • ProcedureBiospecimen Collection

    Undergo collection of blood samples

  • OtherElectronic Health Record Review

    Review of records

  • OtherQuality-of-Life Assessment

    Complete quality-of-life questionnaires

  • OtherSurvey Administration

    Complete surveys

Outcome measures

Primary

  • Biorepository

    Number of biological samples collected and stored (blood)

    Time frame: 5 years

Eligibility criteria

Sex: FemaleAge: 18 Years and olderHealthy volunteers: No
Inclusion Criteria: * Women of all racial and ethnic groups 18 years of age or older * Women with a diagnosis of invasive breast cancer (stages I-III) within the past 7 years * Women who have completed active treatment for breast cancer (surgery, chemotherapy, HER2-directed therapy and radiation) * Prior participation on clinical trials is allowed Exclusion Criteria: * Current receipt of interventional clinical trial participation * Stage IV (metastatic) cancer * Prior history of recurrence (except recurrence following ductal carcinoma in situ) * Inability to give informed consent * Unable to speak English, Spanish, Chinese, or Korean

Study locations (1)

USC / Norris Comprehensive Cancer Center

Los Angeles, California, 90033

Recruiting
Audrey Saghian, MPH · Contact
Bodour Salhia, PhD · Principal Investigator
Breast Cancer Survivorship Biorepository | Cancerify